Clinical trials: Malaria
Malaria
Safety and Efficacy of Methylene Blue Combined With Amodiaquine or Artesunate for Malaria Treatment in Children of Burkina Faso
The purpose of the study is to investigate the safety and efficacy profile of a new paediatric MB formulation combined with AQ or AS and compared to AS-AQ in young African children with uncomplicated falciparum malaria.
- Trial name
- NCT00545935
- Testing
- Methylenblue-Amodiaquine (MB-AQ), Methylenblue-Artesunate (MB-AS), Artesunate-Amodiaquine (AS-AQ)
- Where
- Burkina Faso
- Volunteers
- 186 people
- Sponsor
- Heidelberg University
Malaria (Plasmodium Falciparum)
Controlled Human Malaria Infection by Mosquito Bites Using a Local Strain of Plasmodium Falciparum
The project aims to reproduce the malaria infection cycle using African mosquitoes, namely Anopheles gambiae and a local strain of Plasmodium parasites.
- Trial name
- BB-LaCHMI-01 (NCT07816497)
- Testing
- Controlled Human Malaria Infection
- Where
- Gabon
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Centre de Recherche Médicale de Lambaréné
Uncomplicated Malaria
Pharmacokinetics of Dihydroartemisinin-Piperaquine in the Treatment of Uncomplicated Malaria in Children in Burkina Faso
This will be an open-label trial in Burkina Faso assessing the pharmacokinetics of the antimalarial combination of dihydroartemisinin/piperaquine (DP, Duocotexcin) in children.
- Trial name
- NCT00845533
- Testing
- Dihydroartemisinin-Piperaquine
- Sponsor
- University of California, San Francisco
Uncomplicated Plasmodium Falciparum Malaria
Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria
This study aimed to determine the efficacy, safety and tolerability of the investigational drug KAF156 in combination with a solid dispersion formulation of lumefantrine (LUM-SDF) in pediatric patients (6 months to < 18 years of…
- Trial name
- KALUMI (NCT04546633)
- Testing
- KAF156, LUM-SDF, Coartem
- Where
- 9 sites in Burkina Faso, Côte d’Ivoire and 3 more
- Volunteers
- 295 people
- Sponsor
- Novartis Pharmaceuticals
Malaria
Spatial Repellents for Vector Control
The primary objective of the study is to demonstrate and quantify the protective efficacy of a single Spatial Repellent (SR) product, in reducing malaria infection in a human cohort.
- Trial name
- AEGIS Mali (NCT04795648)
- Testing
- Transfluthrin
- Where
- 2 sites in Mali
- Volunteers
- 1,911 people, healthy volunteers welcome
- Sponsor
- University of Notre Dame
Asymptomatic P.Falciparum Malaria
Artemisia Annua Infusion for the Treatment of Asymptomatic Plasmodium Falciparum Infection
The goal of this clinical trial is to determine whether Artemisia annua dried leaves, used as an infusion, can treat individuals with malaria parasites but no symptoms.
- Trial name
- ART-CT001 (NCT07819825)
- Testing
- Artemisia Annua Leaf, Centaurii herba
- Where
- Gabon
- Volunteers
- 20 people
- Sponsor
- Centre de Recherche Médicale de Lambaréné
Malaria
Dihydroartemisinin (DHA)-Piperaquine for IPT to Prevent Malaria in Children in Burkina Faso
The aim of the study is to determine whether piperaquine plus dihydroartemisinin (DHA-PQ) is as effective, and better tolerated, than sulfadoxine-pyrimethamine plus amodiaquine (SP+AQ), when used for seasonal Intermittent…
- Trial name
- NCT00941785
- Testing
- DHA-PQ, SP-AQ
- Where
- Burkina Faso
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Anemia, Anemia, Iron-Deficiency
Lucky Iron Fish Home Fortification of Iron
The purpose of this research is to determine if cooking with an iron ingot called the Lucky Iron Fish (LIF) increases the hemoglobin status in women of childbearing age living in Preah Vihear, Cambodia.
- Conditions
- Anemia, Anemia, Iron-Deficiency, Hemoglobinopathies
- Trial name
- NCT02341586
- Testing
- Lucky Iron Fish - home fortification system, 18 mg elemental iron, Nutrition Education
- Where
- Cambodia
- Volunteers
- 340 people
- Sponsor
- University of British Columbia
Uncomplicated Malaria
Treatment of Uncomplicated Malaria in Benin
Malaria is a life-threatening disease especially in small children. A high degree of Plasmodium falciparum resistance to chloroquine has already spread to South-Benin where this study is taking place.
- Trial name
- NCT00460369
- Testing
- sulfadoxine-pyrimethamine, artemether-lumefantrine, amodiaquine-artesunate coformulation
- Where
- Benin
- Volunteers
- 240 people
- Sponsor
- Institut de Recherche pour le Developpement
Malaria, Severe Acute Malnutrition
Efficacy and Bio-availability of Artemether-Lumefantrine in Severely Malnourished Children
The general objective of the study is to answer to the question: "Is the current dose of AL less efficacious in the severely malnourished compared to the non-severely malnourished children, and is PK in cause?" We aim to assess…
- Trial name
- MAL-NUT (NCT01958905)
- Testing
- Artemether-lumefantrine fixed combination
- Where
- 2 sites in Mali, Niger
- Volunteers
- 399 people
- Sponsor
- Epicentre
Malaria, Plasmodium Falciparum
A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21
This is a Phase Ib multi-stage Plasmodium falciparum malaria vaccine study to assess the safety and immunogenicity of the blood-stage vaccine candidate RH5.2 virus-like particle (VLP) in Matrix-MTM and the pre-erythrocytic stage…
- Trial name
- NCT05357560
- Testing
- Matrix-M with RH5.2 VLP and/or R21
- Where
- The Gambia
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Uncomplicated Plasmodium Falciparum Malaria
Test Efficacy Study on the Recommended Antimalarial Drugs in the Democratic Republic of the Congo
Malaria remains a public health concern, despite efforts that are invested in the disease control. The Democratic Republic of the Congo (DRC) is one of the most affected countries in Sub Saharan Africa.
- Trial name
- TES2022 (NCT06076213)
- Testing
- Artesunate-amodiaquine, Artemether-lumefantrine
- Where
- 7 sites in Democratic Republic of the Congo
- Volunteers
- 1,260 people
- Sponsor
- Ministry of Public Health, Democratic Republic of the Congo
Malaria, Respiratory Infections
A Trial of Seasonal Malaria Chemoprevention Plus Azithromycin in African Children
The primary objective of this study is to determine whether addition of azithromycin (AZ) to Seasonal Malaria Chemoprevention (SMC) using sulphadoxine/pyrimethamine (SP) +amodiaquine (AQ) will provide an additional reduction in…
- Trial name
- SMCAZ (NCT02211729)
- Testing
- Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin
- Where
- 2 sites in Burkina Faso, Mali
- Volunteers
- 22,090 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Falciparum Malaria
Artesunate+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Falciparum Malaria
In Afghanistan, studies over the past 15 years have shown a high degree of Plasmodium falciparum resistance to chloroquine (80%) and more recently an increasing degree of resistance to sulfadoxine-pyrimethamine monotherapy (12%).
- Trial name
- ASPF (NCT01115439)
- Testing
- artesunate plus sulfadoxine-pyrimethamine (AS+SP)
- Where
- 4 sites in Afghanistan
- Volunteers
- 100 people
- Sponsor
- University of Oxford
Falciparum Malaria
Study to Investigate the Induction of an Protective Immune Response to Malaria
The objective of the study is to induce a protective immune response against malaria in healthy human volunteers. The different parts of the immune response will then be studied.
- Trial name
- NCT00442377
- Testing
- exposure to malaria sporozoites
- Where
- Netherlands
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Pneumonia, Bacterial, Viral Infection
Diagnostic and Prognostic Biomarkers for Childhood Bacterial Pneumonia
Clinical pneumonia is a leading cause of pediatric hospitalization. The etiology is generally bacterial or viral. Prompt and optimal treatment of pneumonia is critical to reduce mortality.
- Conditions
- Pneumonia, Bacterial, Viral Infection, Clinical Pneumonia, Plasmodium Falciparum Malaria
- Trial name
- NCT03996967
- Where
- 3 sites in United States, Netherlands and 1 more
- Volunteers
- 837 people
- Sponsor
- Boston University
Malaria
Innovation Platform
In this study, a prospective evaluation of novel malaria diagnostic tools under development will be performed in malaria-endemic countries to assess their clinical performance for detection of malaria at point-of-care (POC).
- Trial name
- NCT04558528
- Testing
- Novel in vitro diagnostics and medical applications
- Where
- 2 sites in Indonesia, Rwanda
- Volunteers
- 640 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Malaria, Malaria Vivax
This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax Malaria
The goal of this Phase 2b study is to examine the safety and efficacy of the combination of SJ733, an investigational agent, and tafenoquine for the radical cure of uncomplicated P.
- Conditions
- Malaria, Malaria Vivax, Radical Cure
- Trial name
- SJ733-2002 (NCT07430592)
- Testing
- CQ/TQ, SJ733 (3-day)/TQ, SJ733 (2-day ) /TQ
- Where
- Peru
- Volunteers
- 104 people
- Sponsor
- R. Kiplin Guy
Malaria
IPTi in Mozambican Infants for Malaria Prevention
To evaluate if intermittent preventive treatment in infants (IPTi) consisting of SP [Fansidar] given through the EPI scheme alongside routine immunisations at 3, 4 and 9 months of age reduces de incidence of clinical malaria up…
- Trial name
- NCT00209794
- Testing
- Sulfadoxine-Pyrimethamine (Fansidar)
- Where
- Mozambique
- Volunteers
- 1,498 people
- Sponsor
- Hospital Clinic of Barcelona
Healthy Volunteers
Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population
This study will test a new drug (MAM01) to find which doses are safe and could help prevent people from getting malaria for at least 4 months. The study will take place in parts of Africa where malaria is common.
- Trial name
- NCT06408857
- Testing
- MAM01 300 mg SC, MAM01 300 mg IM, MAM01 2000 mg IV
- Where
- 2 sites in Uganda
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Gates Medical Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.